Originally published as JCO Early Release 10.1200/JCO.2004.07.026 on April 26 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zander, A.R. Articles by Jonat, W. Search for Related Content PubMed PubMed Citation Articles by Zander, A.R. Articles by Jonat, W. Related Articles Related Editorial

High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial

From the Transplant Center, University Hospital Hamburg-Eppendorf; Albertinen-Hospital, Hamburg; Centre for Clinical Studies, University Hospital, Freiburg; University Hospital, Ulm; City Hospital, Oldenburg; Humaine Hospital, Bad Saarow; University Hospital, Münster; University Hospital, Magdeburg; Benjamin Franklin Hospital; University Hospital Charité, Berlin; Medical Hospital, Nürnberg; Hospital of the Saarland, Homburg; Evangelische Diakonissenanstalt, Bremen; University Hospital, Kiel, Germany

Address reprint requests to Axel R. Zander, MD, University Hospital Hamburg-Eppendorf, Transplant Center, Bone Marrow Transplantation, Martinistr 52, 20246 Hamburg, Germany; e-mail: zander{at}uke.uni-hamburg.de

PURPOSE: Investigation of high-dose chemotherapy (HD-CT) followed by autologous hematopoietic stem-cell support compared with standard-dose chemotherapy (SD-CT) as adjuvant treatment in patients with primary breast cancer and 10 or more positive axillary lymph nodes.

PATIENTS AND METHODS: Between November 1993 and September 2000, 307 patients were randomized to receive (following four cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m², intravenously every 21 days) either HD-CT of cyclophosphamide 1,500 mg/m², thiotepa 150 mg/m², and mitoxantrone 10 mg/m², intravenously for 4 consecutive days followed by stem-cell support; or SD-CT in three cycles of cyclophosphamide 500 mg/m², methotrexate 40 mg/m², and fluorouracil 600 mg/m² intravenously on days 1 and 8, every 28 days. The primary end point was event-free survival.

RESULTS: After a median follow-up of 3.8 years, 144 events with respect to event-free survival have been observed (HD-CT: 63 events; SD-CT: 81 events). The first event of failure (HD-CT v SD-CT) was an isolated locoregional recurrence (nine v 11), a distant failure (52 v 68), and death without recurrence (two v two). The estimated relative risk of HD-CT versus SD-CT was 0.75 (95% CI, 0.54 to 1.06; P = .095). Overall survival showed no difference (HD-CT: 40 deaths; SD-CT: 49 deaths).

CONCLUSION: There was a trend in favor of HD-CT with respect to event-free survival, but without statistical significance. Further follow-up and a meta-analysis of all randomized studies will reveal the effect of HD-CT as compared with SD-CT as adjuvant treatment in high-risk primary breast cancer.

Supported by the Dr Mildred Scheel Stiftung der Deutschen Krebshilfe, by the Hamburger Krebsgesellschaft, and by the Erich and Gertrud Roggenbuck Foundation.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Related Editorial

• What Is the Role of High-Dose Chemotherapy in the Era of Targeted Therapies?
  Gabriel N. Hortobagyi
  JCO 2004 22: 2263-2266 [Full Text]

This article has been cited by other articles:

				A. R. Zander, C. Schmoor, N. Kroger, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. E. Berdel, M. Koenigsmann, E. Thiel, et al. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up Ann. Onc., June 1, 2008; 19(6): 1082 - 1089. [Abstract] [Full Text] [PDF]

				O. Gluz, U. A. Nitz, N. Harbeck, E. Ting, R. Kates, A. Herr, W. Lindemann, C. Jackisch, W. E. Berdel, H. Kirchner, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial Ann. Onc., May 1, 2008; 19(5): 861 - 870. [Abstract] [Full Text] [PDF]

				N. Duraker, Z. C. Caynak, and B. Bati Is there any Prognostically Different Subgroup among Patients with Stage IIIC (AnyTN3M0) Breast Carcinoma? Ann. Surg. Oncol., February 1, 2008; 15(2): 430 - 437. [Abstract] [Full Text] [PDF]

				A. Kobayashi, H. Hara, M. Ohashi, T. Nishimoto, K. Yoshida, N. Ohkohchi, T. Yoshida, and K. Aoki Allogeneic MHC Gene Transfer Enhances an Effective Antitumor Immunity in the Early Period of Autologous Hematopoietic Stem Cell Transplantation Clin. Cancer Res., December 15, 2007; 13(24): 7469 - 7479. [Abstract] [Full Text] [PDF]

				H. C.F. Moore, S. J. Green, J. R. Gralow, S. I. Bearman, D. Lew, W. E. Barlow, C. Hudis, A. C. Wolff, J. N. Ingle, H. K. Chew, et al. Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623 J. Clin. Oncol., May 1, 2007; 25(13): 1677 - 1682. [Abstract] [Full Text] [PDF]

				A. U. Buzdar Adjuvant Chemotherapy for High-Risk Operable Breast Cancer J. Clin. Oncol., May 1, 2007; 25(13): 1642 - 1644. [Full Text] [PDF]

				N Wilking, E Lidbrink, T Wiklund, B Erikstein, H Lindman, P Malmstrom, P Kellokumpu-Lehtinen, N-O Bengtsson, G Soderlund, G Anker, et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy Ann. Onc., April 1, 2007; 18(4): 694 - 700. [Abstract] [Full Text] [PDF]

				A. Bertuzzi, G. Gullo, L. Rimassa, L. Castagna, and A. Santoro High-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients Ann. Onc., April 1, 2006; 17(4): 719 - 720. [Full Text] [PDF]

				A. Scherwath, A. Mehnert, B. Schleimer, L. Schirmer, F. Fehlauer, R. Kreienberg, B. Metzner, E. Thiel, A. R. Zander, F. Schulz-Kindermann, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects Ann. Onc., March 1, 2006; 17(3): 415 - 423. [Abstract] [Full Text] [PDF]

				N. Kroger, K. Milde-Langosch, S. Riethdorf, C. Schmoor, M. Schumacher, A. R. Zander, and T. Loning Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients Clin. Cancer Res., January 1, 2006; 12(1): 159 - 168. [Abstract] [Full Text] [PDF]

				D. A. Stewart, A. H. G. Paterson, J. D. Ruether, J. Russell, P. Craighead, M. Smylie, and J. Mackey High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study Ann. Onc., September 1, 2005; 16(9): 1463 - 1468. [Abstract] [Full Text] [PDF]

				A. DeMichele, R. Aplenc, J. Botbyl, T. Colligan, L. Wray, M. Klein-Cabral, A. Foulkes, P. Gimotty, J. Glick, B. Weber, et al. Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort J. Clin. Oncol., August 20, 2005; 23(24): 5552 - 5559. [Abstract] [Full Text] [PDF]

				A. Schneeweiss, I. Diel, M. Hensel, S. Kaul, H.-P. Sinn, K. Unnebrink, C. Rudlowski, I. Lauschner, F. Schuetz, G. Egerer, et al. Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy Ann. Onc., November 1, 2004; 15(11): 1627 - 1632. [Abstract] [Full Text] [PDF]

				Y. Nieto, J. J. Vredenburgh, E. J. Shpall, S. I. Bearman, P. A. McSweeney, N. Chao, D. Rizzieri, C. Gasparetto, S. Matthes, A. E. Baron, et al. Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer Clin. Cancer Res., November 1, 2004; 10(21): 7136 - 7143. [Abstract] [Full Text] [PDF]

				Another Trial of High-Dose Chemotherapy with Stem-Cell Support for Breast Cancer Journal Watch (General), July 13, 2004; 2004(713): 2 - 2. [Full Text]

				G. N. Hortobagyi What Is the Role of High-Dose Chemotherapy in the Era of Targeted Therapies? J. Clin. Oncol., June 15, 2004; 22(12): 2263 - 2266. [Full Text] [PDF]